Dekker, Annelot M.
Diekstra, Frank P.
Pulit, Sara L. http://orcid.org/0000-0002-2502-3669
Tazelaar, Gijs H. P.
van der Spek, Rick A.
van Rheenen, Wouter http://orcid.org/0000-0002-5860-1533
van Eijk, Kristel R.
Calvo, Andrea http://orcid.org/0000-0002-5122-7243
Brunetti, Maura
Damme, Philip Van
Robberecht, Wim
Hardiman, Orla
McLaughlin, Russell
ChiĆ², Adriano http://orcid.org/0000-0001-9579-5341
Sendtner, Michael http://orcid.org/0000-0002-4737-2974
Ludolph, Albert C.
Weishaupt, Jochen H.
Pardina, Jesus S. Mora
van den Berg, Leonard H.
Veldink, Jan H.
Funding for this research was provided by:
O. Hardiman is funded by the Health Research Board Clinician Scientist Programme and Science Foundation Ireland
The Thierry Latran Foundation (ALSIBD) and the ALS Association (2284) support R.L. McLaughlin.
This project was supported by the Netherlands Organisation for Health Research and Development (Vici scheme to L.H. van den Berg).
Article History
Received: 28 August 2018
Accepted: 25 March 2019
First Online: 11 April 2019
Competing Interests
: L.H. van den Berg serves on scientific advisory boards for the Prinses Beatrix Spierfonds, Thierry Latran Foundation, Biogen and Cytokinetics; and serves on the editorial board of Amyotrophic Lateral Sclerosis And Frontotemporal Degeneration and The Journal of Neurology, Neurosurgery, and Psychiatry. J.H. Veldink reports that his institute received consultancy fees from Vertex Pharmaceuticals outside the submitted work. O. Hardiman has received speaking honoraria from Novarits, Biogen Idec, Sanofi Aventis and Merck-Serono, has been a member of advisory panels for Biogen Idec, Allergen, Ono Pharmaceuticals, Novartis, Cytokinetics and Sanofi Aventis and serves as Editor-in-Chief of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Other authors have no reported conflicts of interest.